Literature DB >> 15762276

Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers.

Mehrdad Nadji1, Carmen Gomez-Fernandez, Parvin Ganjei-Azar, Azorides R Morales.   

Abstract

Paraffin sections or fine-needle aspiration smears from 5,993 cases of invasive mammary carcinomas were assessed immunohistochemically for estrogen receptor (ER; 1D5) and progesterone receptor (PR; 636) expression. Staining pattern and intensity were correlated with histologic subtypes and nuclear grades of tumors. Positive nuclear staining for ER and PR was observed in 75% and 55% of invasive carcinomas, respectively. In 92% of ER+ cases, diffuse and uniform staining of most tumor cells was observed. In the remaining 8%, a focal ER reaction was seen, usually because of inadequate fixation. In 21% of PR+ tumors, the reaction was heterogeneous or focal but unrelated to fixation. There were no ER-, PR+ tumors. All pure tubular, colloid, and infiltrating lobular carcinomas were ER+. All medullary, apocrine, and metaplastic and most high-nuclear-grade carcinomas were ER-. With monoclonal antibody 1D5 and antigen retrieval, immunohistochemical reaction for ER in breast cancer usually is an all-or-none phenomenon; therefore, quantitation of results is unnecessary. Despite antigen retrieval, inadequate fixation can cause false-negative results; evaluation of internal positive control samples is imperative. ER positivity and negativity are predictable in certain histologic types and nuclear grades of breast cancer. The reaction for PR can be heterogeneous or focal.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15762276     DOI: 10.1309/4wv79n2ghj3x1841

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  127 in total

Review 1.  An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens.

Authors:  E A Rakha; I O Ellis
Journal:  J Clin Pathol       Date:  2007-07-14       Impact factor: 3.411

2.  Digital image analysis outperforms manual biomarker assessment in breast cancer.

Authors:  Gustav Stålhammar; Nelson Fuentes Martinez; Michael Lippert; Nicholas P Tobin; Ida Mølholm; Lorand Kis; Gustaf Rosin; Mattias Rantalainen; Lars Pedersen; Jonas Bergh; Michael Grunkin; Johan Hartman
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

3.  ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast.

Authors:  Semir Vranic; Zoran Gatalica; Hao Deng; Snjezana Frkovic-Grazio; Lisa M J Lee; Olga Gurjeva; Zhao-Yi Wang
Journal:  J Clin Pathol       Date:  2010-11-02       Impact factor: 3.411

4.  In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs).

Authors:  Nobumichi Ohoka; Keiichiro Okuhira; Masahiro Ito; Katsunori Nagai; Norihito Shibata; Takayuki Hattori; Osamu Ujikawa; Kenichiro Shimokawa; Osamu Sano; Ryokichi Koyama; Hisashi Fujita; Mika Teratani; Hirokazu Matsumoto; Yasuhiro Imaeda; Hiroshi Nara; Nobuo Cho; Mikihiko Naito
Journal:  J Biol Chem       Date:  2017-02-02       Impact factor: 5.157

Review 5.  Steroid hormone receptors as prognostic markers in breast cancer.

Authors:  Maggie C Louie; Mary B Sevigny
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

6.  Complete Response to Single-agent Palbociclib in Metastatic Breast Cancer: A Case Report.

Authors:  Sri Lakshmi Hyndavi Yeruva; Mehrbod Som Javadi; Vered Stearns
Journal:  Clin Breast Cancer       Date:  2017-12-21       Impact factor: 3.225

7.  Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis.

Authors:  Jieqiong Liu; Wen Jiang; Kai Mao; Yi An; Fengxi Su; Betty Y S Kim; Qiang Liu; Lisa K Jacobs
Journal:  Breast Cancer Res Treat       Date:  2015-03-13       Impact factor: 4.872

8.  Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation.

Authors:  Nobumichi Ohoka; Yoko Morita; Katsunori Nagai; Kenichiro Shimokawa; Osamu Ujikawa; Ikuo Fujimori; Masahiro Ito; Youji Hayase; Keiichiro Okuhira; Norihito Shibata; Takayuki Hattori; Tomoya Sameshima; Osamu Sano; Ryokichi Koyama; Yasuhiro Imaeda; Hiroshi Nara; Nobuo Cho; Mikihiko Naito
Journal:  J Biol Chem       Date:  2018-03-15       Impact factor: 5.157

9.  Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling.

Authors:  Shanhu Li; Hongtao Wang; Liu Hong; Wei Liu; Fang Huang; Jian Wang; Peng Wang; Xiaoqing Zhang; Jianguang Zhou
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

10.  Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.

Authors:  Gabriele Carlinfante; Paola Baccarini; Debora Berretti; Tiziana Cassetti; Maurizio Cavina; Rita Conigliaro; Alessandro De Pellegrin; Luca Di Tommaso; Carlo Fabbri; Adele Fornelli; Andrea Frasoldati; Giorgio Gardini; Luisa Losi; Livia Maccio; Raffaele Manta; Nico Pagano; Romano Sassatelli; Silvia Serra; Lorenzo Camellini
Journal:  Virchows Arch       Date:  2014-05-08       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.